Document is current
Any future updates will be listed below
-
Authors
Kharfan-Dabaja, Mohamed A. http://orcid.org/0000-0001-7394-5185
Labopin, Myriam http://orcid.org/0000-0003-4514-4748
Bazarbachi, Ali http://orcid.org/0000-0002-7171-4997
Ciceri, Fabio http://orcid.org/0000-0003-0873-0123
Finke, Jürgen
Bruno, Benedetto
Bornhäuser, Martin
Gedde-Dahl, Tobias
Labussière-Wallet, Hélène
Niittyvuopio, Riitta
Valerius, Thomas
Angelucci, Emanuele
Brecht, Arne
Caballero, Dolores
Kuball, Jürgen http://orcid.org/0000-0002-3914-7806
Potter, Victoria
Schmid, Christoph
Tischer, Johanna
Zuckerman, Tsila http://orcid.org/0000-0002-6204-977X
Benedetti, Fabio
Blaise, Didier http://orcid.org/0000-0002-5684-9447
Diez-Martin, Jose Luis
Sanz, Jaime http://orcid.org/0000-0001-6934-4619
Ruggeri, Annalisa http://orcid.org/0000-0002-7261-2765
Brissot, Eolia
Savani, Bipin N. http://orcid.org/0000-0002-3304-9965
Giebel, Sebastian http://orcid.org/0000-0002-4827-4401
Nagler, Arnon http://orcid.org/0000-0002-0763-1265
Mohty, Mohamad http://orcid.org/0000-0002-7264-808X
-
License Information
Text and Data Mining valid from 2021-04-30
Version of Record valid from 2021-04-30
-
More Information
Article History
Received: 27 November 2020
Revised: 5 February 2021
Accepted: 14 April 2021
First Online: 30 April 2021
Conflict of interest
: MAK-D reports consultancy for Daiichi Sankyo and Pharmacyclics; JK: reports research support from Novartis, Miltenyi Biotech and Gadeta and shareholder and scientific cofounder of Gadeta; MM: Consultancy, research funding, honoraria and speaker’s bureau for Sanofi, Janssen, Amgen, Takeda, Celgene, Glaxo Smith Kline, Jazz pharmaceuticals, Adaptive, Stemline, Bristol Myers Squibb, Novartis. The remaining authors declare no competing interests.
